Drugs / Bavtavirine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05585307 | Oct 2022 → Feb 2024 | HIV infectious disease | Gilead Sciences | Completed | Met primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bavtavirine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05585307 ↗ |
| Known as | Bavtavirina | ChEMBL registry synonym — accepted as the source's own label CHEMBL5314504 ↗ |
| Modality | Small molecule | — CHEMBL5314504 ↗ |
| Route | Oral | “Administered orally” NCT05585307 ↗ |